BioSpace News Archive

The results of a clinical study of Synchrony Medical’s LibAirty™ Airway Clearance System showed that the system was twice as effective in clearing mucus from the lungs of patients with chronic lung disease when compared to the standard of care therapy.

Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).

Oxford BioDynamics, Plc, a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform and Bupa, the UK’s leading health insurer, announce a strategic agreement to give Bupa patients access to OBD’s EpiSwitch CiRT.

AN2 Therapeutics, Inc. today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease.

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.

G1 Therapeutics, Inc. will host a webcast and conference call to provide a financial and corporate update for the third quarter 2023 on Wednesday November 1, 2023, at 8:30 a.m. ET.

Vanqua Bio announced today that the company will participate in the Leerink Partners Biopharma Private Company Connect, which is being held virtually October 25-26.

Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced the appointment of Ian Lachlan McLean, M.D., Ph.D. as its chief medical officer.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer is presenting its groundbreaking results of its ColoFuture Study.

Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced that recent data on AD109 (aroxybutynin/atomoxetine) will be featured in an oral presentation at World Sleep 2023 symposium in Rio de Janeiro, Brazil.